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Implication for health policy/practice/research/medical education:
Our results demonstrated the in vivo antibacterial activity of roselle calyx extract against Staphylococcus aureus using a novel 
Drosophila infection model platform that shall emphasize the idea to explore the use of roselle calyx extract as a source to 
discover novel anti-staphylococcal agents.
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Introduction: The emergence of antibiotic-resistant Staphylococcus aureus is a major threat 
for worldwide communities. To overcome such serious problem, the discovery of novel 
antibacterial agents through exploration of diverse potential sources is essential. The aim 
of this research was to investigate the in vivo anti-staphylococcal activity of roselle (Hibiscus 
sabdariffa L.) calyx extract against S. aureus in fruit flies (Drosophila melanogaster) model of 
infection. 
Methods: Roselle calyces were dried and extracted with ethanol using maceration method. 
Wildtype fruit flies were infected with S. aureus and subjected to survival assay, bacterial load 
examination, and gene expression analysis, in the presence or absence of roselle calyx extract. 
Survival and bacterial load analysis were subsequently performed on immunodeficient fruit 
flies using similar protocols. 
Results: Reduction of host survivorship accompanied by increasing level of bacterial proliferation 
was observed in group of wildtype fruit flies infected with S. aureus. These phenotypic events 
were further augmented in mutant flies devoid of component for antibacterial immune 
responses. Nevertheless, reduction of bacterial load and improvement of host survival were 
demonstrated in either wildtype or immunodeficient fruit flies upon treatment with roselle 
calyx extract after bacterial challenge, irrespective of immune status. 
Conclusion: Collectively, our results demonstrated the in vivo antibacterial activity of roselle 
calyx extract against S. aureus in Drosophila model of infection and this was not due to 
induction of immune response in the host.
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Introduction
Antibiotics are considered as the most used class of drugs 
in the world. Between 2000 and 2010, the consumption 
of antibiotics reached more than 30% of the total use 
of medicines worldwide (1). In Indonesia itself, the 
utilization of antibiotics even reached 80% of total drugs 
consumed between 2002 to 2005 (2). Unfortunately, in 
some cases, antibiotics were purchased in the absence 
of proper examination and decision from physician or 
even without the needs of prescription, implicating the 
irrational practice of antibiotics utilization. Consequently, 
in addition to other contributing factors, the emergence of 
antibiotic-resistant bacteria has been constantly reported 
(1,3,4).
The emergence of bacterial strains that are resistant to 
antibiotics is a major concern for public health (3-5). One 
of the pathogenic bacteria that presents serious threat to 
human population is Staphylococcus aureus (6), especially 
after the emergence of methicillin-resistant S. aureus 
(MRSA) (7). To overcome this life-threatening problem, 
the discovery of novel antibacterial agents through 
exploration of diverse potential sources is essential (4, 
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8). One of promising sources for such efforts is roselle 
(Hibiscus sabdariffa L.). The ethanolic extract of roselle’s 
calyx has been shown to yield excellent in vitro antibacterial 
effect against several Gram-positive pathogenic bacteria 
(9-11), including S. aureus and MRSA (12,13). However, 
despite such promising antibacterial effect, no in vivo 
experiment has been carried out to further clarify the anti-
staphylococcal activity of roselle calyx ethanolic extract.
Recently, we introduced an inexpensive in vivo 
platform to assess the anti-staphylococcal activity of 
green algae Ulva reticulata (14). In this platform, we 
used wild type and immunodeficient fruit fly (Drosophila 
melanogaster) as host organisms in S. aureus infection 
and made use of two simple phenotypic assays: survival 
assay and determination of bacterial load (14). To date, 
D. melanogaster has been recognized as a pioneer model 
organism in the revelation of important signaling pathways 
related to immunity against not only bacterial infection 
(15,16) but also viral infection (17-19). In addition to that, 
D. melanogaster has been introduced as one of emerging 
human disease models (20,21) and considered as one of 
suitable model organisms in the drug discovery (22-25). 
Drosophila melanogaster offers great advantages as 
an in vivo model system in antibacterial drug discovery 
research. In addition to the fact that it has been shown as an 
appropriate host for S. aureus (14,26-28), D. melanogaster 
shares high degree of genetic similarity with human (up 
to 75%) (21) which suggests high possibility for getting 
the same results upon clinical trial on human subjects. 
Moreover, the use of fruit flies as a model organism raises 
almost no ethical issues and requires little effort in the 
stock maintenance (20,21,29). Based on such advantages, 
we carried out this research to investigate the in vivo anti-
staphylococcal activity of roselle extract against S. aureus 
in fruit flies model of infection.
Materials and Methods
Bacterial strains and fly stocks
Fresh culture of S. aureus ATCC 29213 strain was used as 
an infectious agent in the entire experiments. To obtain 
the appropriate inoculum, the bacteria was cultured in 
Nutrient Broth (NB) medium at 37°C for 1 × 24 hours, 
collected and washed thoroughly with PBS followed by 
quantification using spectrophotometry method. The 
inoculum of S. aureus was suspended in PBS prior to use 
in the experiments. The following lines of Drosophila were 
used in this study: w1118 as genotype (background) control 
and spzrm7/TM6 as immunodeficient fly line (gifts from Prof. 
Yoshinobu Nakanishi, Kanazawa University) which has 
impaired activity of Spätzle. All fly lines were maintained 
with standard cornmeal-agar medium at 25°C.
Extract preparation
Samples of roselle (Hibiscus sabdariffa L.) calyces were 
obtained from Makassar area, South Sulawesi, Indonesia. 
These samples were sorted and subjected to maceration 
procedure using 96% ethanol for 1 x 24 hours and re-
macerated for 1 x 24 hours. All filtrates were collected 
and further processed using rotavapor until extract with 
appropriate thickness were obtained. The resulting extract 
was stored in a brown silica container. 
Fly infection and assays for survival and bacterial growth
Infection experiment was carried out on either 
background control or immunodeficient fly line using 
pricking method, in which bacteria was introduced into 
the thorax of male adult flies, as described previously 
(14). In brief, flies at age of 4–7 days after eclosion (10 
flies per vial, 3 vials in each experiment) were subjected 
to bacterial pricking (6 × 105 cfu/mL per fly) and further 
maintained at 29°C. Pricked flies were then subjected to 
either survival assay or colony forming assay as described 
previously (14). For the survival assay, the flies were 
pricked with S. aureus and maintained in vials in the 
presence or absence of treatments and number of live 
flies at each group was recorded daily during experiment. 
For the colony forming assay, flies were pricked with S. 
aureus and maintained in vials in the presence or absence 
of treatments. At a given time, live flies were taken 
from each group and mechanically processed using a 
micropestle in PBS solution. Homogenates obtained from 
each group were subsequently prepared at a serial dilution 
and then plated on Vogel-Johnson agar medium. Number 
of colonies appeared after incubation was expressed as 
colony-forming unit (cfu) per ml. Groups of healthy flies 
pricked with PBS were used as controls in both survival 
and colony forming assays. 
Gene expression analysis
Total RNA was extracted from five live Drosophila 
harvested from each group of treatments at 48 hours post 
infection and homogenized manually in the Treff tube 
using Micropestle followed by further processing using 
SV Total RNA Isolation System (Promega) according to 
the manufacturer’s protocol. Analysis of drosomycin (drs) 
level was carried out using one set of drs primer (sequence 
of drs forward primer: 5’ - CGT GAG AAC CTT TTC CAA 
TAT GAT G - 3’ and sequence of drs reverse primer: 5’ - 
TCC CAG GAC CAC CAG CAT - 3’) in a 20 µl reaction 
volume using GoTaq® 1-Step RT-qPCR System (Promega), 
as per manufacturer’s instruction. Ribosomal protein rp49 
was used as host reference gene and examined by using 
one set of rp49 primer (sequence of rp49 forward primer: 
5’ - GAC GCT TCA AGG GAC AGT ATC TG - 3’ and 
sequence of rp49 reverse primer: 5’ - AAA CGC GGT 
TCT GCA TGA G - 3’) using the same protocol. Rotor-
Gene Q thermal cycler (Qiagen, Germany) was used 
with the following profile: 37°C for 15 minutes, 95°C for 
10 minutes, and 40 cyclic repeats of 95°C for 10 seconds 
and 60°C for 30 seconds, and 72°C for 30 seconds. A 
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standard melt curve analysis was carried out to confirm 
that only the expected product had been amplified. The 
abundance of drs relative to the host reference gene rp49 
was determined using qGENE software. 
Data processing and statistical analysis
Results obtained from at least three independent biological 
replicates were processed using GraphPad Prism® 7. 
Survival curve was prepared as a Kaplan-Meier curve 
and followed by log-rank analysis. For analysis of CFU 
and mRNA level of drs, data were prepared as bar graphs 
and analyzed statistically using one-way ANOVA. For all 
statistical analysis, data were presented as mean ± S.D and 
P values of less than 0.05 were considered significant. 
Results 
Dose-dependent toxicity of roselle calyx extract in adult 
Drosophila melanogaster
In this experiment, we used in vivo Drosophila platform to 
assess the antibacterial effect of roselle on S. aureus. Prior 
to antibacterial activity assessment, we carried out a simple 
survival assay to determine the safest concentration of 
roselle calyx extract to be used in the further experiments. 
As shown in Figure 1, D. melanogaster w1118 (Figure 1A) 
and spz mutant line (Figure 1B) were succumbed to 
immediate and gradual death upon ingestion of roselle 
calyx extract at high concentrations (20% and 10% w/w, 
respectively). However, the survival of flies was seemingly 
not affected once maintained in foods containing roselle 
calyx extracts at lower concentration (5% w/w), indicating 
the toxicity effect of this extract on D. melanogaster was 
occurred in a dose-dependent manner. Therefore, to rule 
out the possible influence of lethal effect of extract, we 
used roselle calyx extract at a concentration of 5% (w/w) 
in further experiments.
Improvement of Drosophila melanogaster survival rate by 
roselle calyx extract under infection condition
Staphylococcus aureus is a gram-positive bacterium that has 
been shown to exert wide-ranging negative effect on many 
organisms including humans (31) and D. melanogaster 
(27). As shown in Figure 2A, infection of D. melanogaster 
w1118 by S. aureus resulted in the reduction of flies’ survival 
rate. However, treatment of S. aureus-infected Drosophila 
w1118 with tetracycline, a potent bacteria protein synthesis 
inhibitor, was sufficient to prevent host early death 
phenotype, as documented by previous investigator (27) 
and recently confirmed by our group (14). In addition to 
that, treatment using ethanolic extract of roselle calyx at 
concentration of 5% was able to improve the survival of 
S. aureus-infected D. melanogaster, demonstrating the in 
vivo antibacterial activity of roselle calyx extract against S. 
aureus at the corresponding concentration. 
Inhibition of Staphylococcus aureus growth by roselle 
calyx extract
Decreased survivorship of D. melanogaster upon S. aureus 
infection has been shown to be associated with increased 
Figure 1. Ingestion of roselle calyx extract reduced the survival of 
D. melanogaster in a concentration-dependent manner. Adult flies 
w1118 (A) and spzrm7/TM6 (B) with age of 4-7 days were fed roselle calyx 
extract-containing food at three different concentrations (5, 10, and 
20 %) and incubated at 25°C. Number of dead flies were observed 
daily and fly survival was carried out using a Kaplan-Meier-Log Rank 
analysis.
Figure 2. Improvement of host survival and reduced bacterial load 
in infected w1118 flies in the presence roselle calyx extract. Adult w1118 
flies at 4-7 days after eclosion were infected with 6 x 105 cfu/ml of S. 
aureus by pricking, incubated at 25°C in the presence of 5% roselle 
calyx extract, and subjected to fly survival (A) and bacterial load (B) 
analysis. Flies treated with tetracycline at 200 µg/ml were used as a 
positive control group.
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bacterial load (27) and inhibition of bacterial growth by 
antibiotics improved the survival of infected host (27, 32). 
Taken this into account, we anticipated the reduction of 
bacterial load will be seen in the infected flies treated with 
roselle calyx extract. To examine this, we carried out a 
colony forming assay. As a result, we found that treatment 
of S. aureus-infected flies with either tetracycline or 
roselle calyx extract was certainly beneficial to reduce the 
bacterial load (Figure 2B), further supporting the notion 
that inhibition of bacterial growth by antibiotic or certain 
extract with potent antibacterial activity could lead to 
increased survivorship of infected flies.
Anti-staphylococcal activity of roselle calyx extract was 
not due to increased expression of antimicrobial peptide 
Drosomycin
Upon infection with gram-positive bacteria, Drosophila 
produced several antimicrobial peptides (AMP) that serve 
as part of humoral immune responses (15,33). One of the 
well-characterized AMPs in Drosophila against gram-
positive bacteria such as S. aureus is called drosomycin 
(33), which is expressed by drs gene. To confirm whether 
drosomycin plays a role in the anti-staphylococcal activity 
of roselle extract, we examined the expression level of drs 
gene using RT-qPCR method. We found that the expression 
of drs was significantly induced upon S. aureus infection 
and such state was also observed in the tetracycline-
treated or the extract-treated S. aureus-infected groups 
(Figure 3). Furthermore, the expression of drs was not 
statistically significant among all treatments, suggesting 
that treatments using either tetracycline or roselle calyx 
extract did not aggravate increased induction of drs. This 
result indicates that antibacterial activity of tetracycline 
or roselle calyx extract at the given concentration was not 
related to the increased production of drosomycin. 
Anti-staphylococcal effects of roselle calyx extract in the 
immunodeficient model system
Improvement on the survival rate of S. aureus-infected 
host and reduction of the in vivo bacterial load upon 
treatment with roselle calyx extract were most likely not 
due to the increased production of drosomycin. Therefore, 
we considered that the protection might be conferred as 
the result of interaction between antibacterial compounds 
contained in the extract and S. aureus found in infected 
flies. To further clarify this, we conducted infection 
experiments on a mutant fly line lacking for Spätzle, an 
important component in the Toll-mediated humoral 
immune response against S. aureus. As shown in Figure 4, 
Spätzle-immunodeficient mutant flies succumbed earlier 
(Figure 4A) with a little higher bacterial load (Figure 
4B) than the genotype control flies (compared to Figure 
2A and 2B) upon infection with S. aureus, clarifying the 
important role of Toll-mediated protection against S. 
aureus infection. Nevertheless, treatment of S. aureus-
Figure 3. Anti-staphylococcal protection of roselle calyx extract 
was achieved independent of humoral immunity stimulation. 
Adult w1118 flies at 4-7 days after eclosion were infected with 6 
x 105 cfu/ml of S. aureus by pricking, incubated at 25°C in the 
presence of 5% roselle calyx extract, and subjected to RNA 
isolation followed by drosomycin mRNA level quantification by 
RT-qPCR. Expression of reference gene rp49 was used as the 
internal control.
Figure 4. Enhancement of host survivorship and impaired 
bacterial proliferation in infected immunodeficient spzrm7/TM6 flies 
in the presence roselle calyx extract. Adult spzrm7/TM6 flies at 4-7 
days after eclosion were infected with 6 x 105 cfu/ml of S. aureus 
by pricking, incubated at 25°C in the presence of 5% roselle calyx 
extract, and subjected to fly survival (A) and bacterial load (B) 
analysis. Flies treated with tetracycline at 200 µg/ml were used as 
a positive control group.
infected mutant fly line lacking for Spätzle with ethanolic 
extract of roselle calyx at concentration of 5% (w/w) was 
sufficient to inhibit bacterial proliferation (Figure 4B) 
and led to the improvement of mutant flies’ survivorship 
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(Figure 4A). Taken together, our results demonstrated 
the anti-staphylococcal activity of roselle calyx extract 
in Drosophila and further clarified that its antibacterial 
action was not due to the increased activity in Spätzle-
mediated production of drosomycin.
Discussion
Infusion prepared from roselle calyces has been generally 
used by populations from India and countries of Africa as 
a traditional remedy to treat various illnesses, including 
infectious diseases (30) and its extract has been shown 
to yield excellent in vitro antibacterial activities against 
several bacteria, including S. aureus (12,13). However, 
until now, limited information was available regarding 
the in vivo anti-staphylococcal activity of this particular 
preparation. Here, we used a simple and inexpensive in 
vivo Drosophila platform to assess the anti-staphylococcal 
activity of roselle calyx extract. 
As a well-known member of the gram-positive bacteria, 
Staphylococcus aureus has been shown to cause extensive 
negative impacts on the health of many organisms 
including humans (31) and D. melanogaster (27), thus 
would be a prospective target for antibacterial drug 
discovery. Recently, we found that Ulva reticulata extract 
that has been demonstrated to yield a broad antibacterial 
activity in the in vitro experiment was able to inhibit S. 
aureus growth in adult Drosophila and this led to a decline 
in the infected host mortality (14). Taken this into account, 
we used a similar approach in this research by carrying 
out straight-forward survival assays and colony forming 
assays on the S. aureus-infected flies in the presence of 
roselle calyx extract. 
Survival assay and colony forming assay are simple yet 
powerful methods to examine the pharmacological effect 
of treatment given to live objects that are under certain 
pressure (in this case, S. aureus infection). From the results, 
it can be seen that improved survivorship of infected 
flies was accompanied by the decreased propagation 
of S. aureus in genotype control and immunodeficient 
mutant fly groups that were treated with food containing 
roselle calyx extract, suggesting the antibacterial effect 
of this extract was extended to the individuals in vivo 
independent on their immune response status and at the 
same time demonstrating the applicability of survival 
and colony forming assays to be used together with our 
established in vivo platform to screen for medicinal plants 
that are potential as sources to discover antibacterial 
agents against S. aureus.
Conclusion
In this research, for the first time, we demonstrated the 
in vivo antibacterial effect of roselle calyx extract against 
S. aureus using a straight-forward and inexpensive 
Drosophila platform system. In conjunction with currently 
available in vitro high-throughput screening method, 
this system would serve as a powerful in vivo approach 
to clarify the antibacterial activity of not only roselle 
calyx extract but also numerous medicinal plant extracts 
prior to be used in further efforts to discover important 
antibacterial compounds from the corresponding sources. 
Moreover, this approach will be useful to improve our 
chance to obtain more appropriate compounds in the 
initial screening as well as to rule out toxic compounds 
that are harmful to the eukaryotic cells. 
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